What's Happening?
Researchers at Memorial Sloan Kettering Cancer Center have developed a new CAR T-cell therapy targeting the urokinase plasminogen activator receptor (uPAR) to treat solid tumors. This approach addresses the challenge of targeting solid tumors, which often
lack consistent surface markers and are protected by dense tissue. The study, published in Cell, shows that uPAR is elevated in several human cancer types and is associated with aggressive cancer traits. The therapy demonstrated effectiveness in shrinking various solid tumors, including lung, pancreatic, and ovarian cancers, in preclinical models. The research suggests that targeting uPAR could lead to significant advancements in treating solid tumors.
Why It's Important?
This development represents a significant breakthrough in cancer treatment, particularly for solid tumors that have been difficult to target with existing therapies. By focusing on uPAR, researchers can potentially improve the effectiveness of CAR T-cell therapy, offering new hope for patients with aggressive cancers. The study's findings could lead to more personalized and effective treatment options, reducing the burden of cancer and improving patient outcomes. Additionally, the research highlights the potential for combining CAR T-cell therapy with other treatments to enhance therapeutic effects, paving the way for innovative cancer treatment strategies.
